Corticosteroid therapy in fibrotic interstitial lung disease: a modified Delphi survey

Manuela Funke-Chambour; Philipp Suter; Gisli R Jenkins; Leticia Kawano-Dourado; Christopher J Ryerson; Athol U Wells; Michael Kreuter; Kerri A Johannson; Delphi Survey Participants

doi:10.1183/23120541.00561-2024

Corticosteroid therapy in fibrotic interstitial lung disease: a modified Delphi survey

ERJ Open Res. 2024 Oct 7;10(5):00561-2024. doi: 10.1183/23120541.00561-2024. eCollection 2024 Sep.

Authors

Affiliations

¹ Department for Pulmonology, Allergology and Clinical Immunology, Inselspital, University Hospital Bern, Bern, Switzerland.
² Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, UK.
³ Hcor Research Institute, Hospital do Coracao, Sao Paulo, Brazil and Pulmonary Division, Heart Institute (InCor), University of Sao Paulo, Sao Paulo, Brazil.
⁴ Department of Medicine and Centre of Heart Lung Innovations, University of British Columbia, Vancouver, BC, Canada.
⁵ Royal Brompton and Harefield NHS Foundation Trust, London, UK.
⁶ Mainz Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center, Mainz, Germany.
⁷ Department of Pulmonary, Critical Care and Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany.
⁸ These authors contributed equally.
⁹ Department of Medicine, University of Calgary, Calgary, AB, Canada.

Abstract

The use of steroids in fibrotic interstitial lung diseases is founded on limited evidence. This modified Delphi survey sheds light on current clinical practices. Given the risks of steroids, clinical trials are needed to evaluate efficacy and harm. https://bit.ly/3VkgvbS.